Browse studies

Find your next paid study

25,431 recruiting studies available now

A Multi-centre, Randomised, Double-blind, Placebo-controlled, Phase IIIb Trial to Evaluate the Effect of Survodutide on Cardiac Structure and Function of Participants With Overweight or Obesity and Metabolic Dysfunction-associated Steatotic Liver Disease (MASLD); (ELEVATE-LIVER)

This study is for adults aged 18 years and older who have a type of fatty liver disease called metabolic dysfunction-associated steatotic liver disease (MASLD)…

ObesityMetabolic Dysfunction-associated Steatotic Liver Disease

Estimated

~$50 – $2,250

Actual pay is set by the research site.

Boehringer IngelheimNCT07850063

Phase 4

A Prospective, Randomized, Single-blind, Study to Assess Drowsiness, Cognition, Fall Risk, and Electroencephalographic (EEG) Dynamics After Oral Metaxalone Tablets 640 mg (M640) Versus Metaxalone 800 mg in Healthy Participants

Health participants take a single dose, perform testing, washout for one week, take a single dose of different formulation, and perform testing for comparison …

Healthy Participants

Estimated

~$25 – $1,400

Actual pay is set by the research site.

Primus PharmaceuticalsNCT07801066

Phase 3

An Open-Label Study to Assess the Efficacy and Safety of Multiple Doses of Salanersen (BIIB115) Delivered Intrathecally to Treatment-Naïve, Presymptomatic Infants With Genetically Diagnosed Spinal Muscular Atrophy

In this study, researchers will learn more about the effects and safety of BIIB115, also known as salanersen. Specifically, researchers will learn more about …

Muscular Atrophy, Spinal

Estimated

~$50 – $2,250

Actual pay is set by the research site.

BiogenNCT07221669

Phase 1

A Phase I Study to Assess the Safety and Antitumor Activity of Autologous B7-H3 Chimeric Antigen Receptor T Cells in Previously Treated Extensive-Stage Small Cell Lung Cancer With Recurrent or Refractory Disease

Background: Small cell lung cancer (SCLC) is the deadliest form of lung cancer. Extrapulmonary neuroendocrine cancer (EPNEC) is a similar type of cancer that …

Recurrent Small Cell Lung CancerExtensive-Stage Small Cell Lung CancerSmall Cell Lung Cancer+6 more

Estimated

~$150 – $2,700

Actual pay is set by the research site.

National Cancer Institute (NCI)

Phase 3

A Phase III, Multicenter, Double-Blind, Placebo-Controlled, Treat-Through Study to Assess the Efficacy and Safety of Induction and Maintenance Therapy With RO7790121 in Patients With Moderately to Severely Active Crohn's Disease

This Phase III, multicenter, double-blind, placebo-controlled treat-through study will evaluate the efficacy and safety of induction and maintenance therapy wi…

Moderately to Severely Active Crohns Disease

Estimated

~$50 – $2,250

Actual pay is set by the research site.

Hoffmann-La RocheNCT06819878

Tissue Procurement and Natural History Study of Neuroendocrine Neoplasms (NENs) Including Adrenocortical Carcinoma (ACC)

Background: Neuroendocrine neoplasm (NENs)are rare cancers arising from the neuroendocrine cells and can affect almost any part of the body. They vary from lo…

Neuroendocrine TumorsCarcinoma, Neuroendocrine

Estimated

~$10 – $675

Actual pay is set by the research site.

National Cancer Institute (NCI)NCT05237934

Phase 2

Central and Peripheral GABA and Glutamate Modulation With Intravenous Ketamine for Treatment-Resistant Depression (G2K): A Randomized, Double-Blind, Placebo-Controlled Study

The purpose of this study is to to evaluate the relationships between peak (% change from baseline) central GABA and Glu levels during a 40-min IV ketamine or …

Depressive Disorder, Treatment-ResistantTreatment Resistant Depression (TRD)

Estimated

~$75 – $2,000

Actual pay is set by the research site.

Mayo ClinicNCT06668571

Observational

Comparing the Addition of Inspiratory Muscle Training (IMT) to Usual Care Physical Therapy in Hospitalized Patients With Heart Failure Awaiting Advanced Therapies: a Single-center Pilot Feasibility Study

The primary objective of this study is to evaluate the feasibility and safety of inspiratory muscle training (IMT) when implemented as part of routine inpatien…

Heart FailureHeart Failure New York Heart Association Class IIIHeart Failure New York Heart Association Class IV

Estimated

~$10 – $1,125

Actual pay is set by the research site.

NYU Langone HealthNCT07862738

High Sensitivity Screening of Compound Libraries to Discover a Drug for the Treatment of Sickle Cell Disease

This study will collect representative blood samples from healthy children and adults and from children and adults who have unique red blood cell features that…

Sickle Cell TraitSickle Cell DiseaseSickle Cell Anemia

Estimated

~$10 – $675

Actual pay is set by the research site.

National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)NCT00542230

Phase 2

A Phase 2A/B, Multi-center, Open-Label Study Evaluating the Efficacy and Safety of Dabogratinib (TYRA-300) in Participants With Low Grade Upper Tract Urothelial Carcinoma (SURF303)

A Phase 2A/B study of Dabogratinib (TYRA-300) in Low Grade Upper Tract Urothelial Carcinoma

Low Grade Upper Tract Urothelial Carcinoma

Estimated

~$75 – $2,800

Actual pay is set by the research site.

Tyra Biosciences, IncNCT07265947

Phase 2

A Phase IIb, Multicentre, Randomised, Double Blind, Placebo Controlled, Three-arm Parallel-group Study to Evaluate the Efficacy, Safety, and Tolerability at Week 24 of 2 Doses of CHF10067 (Zampilimab),in Participants With Idiopathic Pulmonary Fibrosis

The purpose of this study is to evaluate the efficacy, safety, and tolerability at Week 24 of 2 doses of CHF10067 (zampilimab) in participants with idiopathic …

Idiopathic Pulmonary Fibrosis

Estimated

~$75 – $3,000

Actual pay is set by the research site.

Chiesi Farmaceutici S.p.A.NCT07516951

Phase 3

A Global, Interventional, Open-label Trial of T-DXd-based Therapy Followed by Palbociclib, Endocrine Therapy and Dual HER2 Blockade in First-line HER2+/ HR+ Advanced or Metastatic Breast Cancer and Retreatment With T-DXd (DB-Guide)

This study will evaluate a structured sequential treatment strategy starting with T-DXd + pertuzumab upfront therapy, followed by an optimized maintenance ther…

Advanced Breast CancerMetastatic Breast CancerHER2 Positive+1 more

Estimated

~$50 – $2,250

Actual pay is set by the research site.

Daiichi SankyoNCT07683754